A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 16, Issue 5-6, 2015, Pages 353-358

  Shibuya, Kazumoto ^a   Misawa, Sonoko ^a   Kimura, Hideki ^b   Noto, Yu Ichi ^c   Sato, Yasunori ^d   Sekiguchi, Yukari ^a   Iwai, Yuta ^a   Mitsuma, Satsuki ^a   Beppu, Minako ^a   Watanabe, Keisuke ^a   Fujimaki, Yumi ^b   Tsuji, Yukiko ^c   Shimizu, Toshio ^b   Mizuno, Toshiki ^c   Nakagawa, Masanori ^c   Sawaguchi, Kyoko ^d   Hanaoka, Hideki ^d   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

amyotrophic lateral sclerosis; clinical trial; Mexiletine; nerve excitability; sodium current

Indexed keywords

MEXILETINE; RILUZOLE; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DEFECATION SYNCOPE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TRIGEMINAL PULSE; VERY ELDERLY; ANIMAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MOTOR EVOKED POTENTIAL; NERVE CONDUCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVOKED POTENTIALS, MOTOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEXILETINE; MIDDLE AGED; NEURAL CONDUCTION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84945114875     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2015.1038277     Document Type: Article

References (30)

1. Kuwabara S, Shibuya K, Misawa S. Fasciculations, axonal hyperexcitability, and motoneuronal death in amyotrophic lateral sclerosis. Clin Neurophysiol. 2014; 125: 872-3.
2. Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve. 1994; 17: 1243-9.
3. Kanai K, Kuwabara S, Misawa S, Tamura N, Ogawara K, Nakata M, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006; 129: 953-62.
4. Shibuya K, Misawa S, Arai K, Nakata M, Kanai K, Yoshiyama Y, et al. Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: an immunohistochemical study. Exp Neurol. 2011; 232: 149-53.
5. Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006; 117: 1458-66.
6. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011; 377: 942-55.
7. Kuwabara S, Sonoo M, Komori T, Shimizu T, Hirashima F, Inaba A, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve. 2008; 37: 426-30.
8. Bae JS, Sawai S, Misawa S, Kanai K, Isose S, Kuwabara S. Differences in excitability properties of FDI and ADM motor axons. Muscle Nerve. 2009; 39: 350-4.
9. Shibuya K, Misawa S, Nasu S, Sekiguchi Y, Mitsuma S, Beppu M, et al. Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons. J Neurol Neurosurg Psychiatry. 2013; 84: 969-72.
10. Kanai K, Shibuya K, Sato Y, Misawa S, Nasu S, Sekiguchi Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012; 83: 734-8.
11. Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current and its effect on excitability in motor neurons cultured from mutant SOD1 mice. J Physiol. 2005; 563: 843-54.
12. Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol. 2009; 215: 368-79.
13. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008; 119: 497-503.
14. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21.
15. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008; 275: 69-73.
16. Medical Research Council. Aids to examination of the peripheral nervous system. Vol. 1. London: Her Majesty's Stationary Office., 1976.
17. Vucic S, Kiernan MC. Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology. 2007; 69: 1828-35.
18. Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 50-4.
19. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11: 456-60.
20. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010; 9: 481-8.
21. Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler. 2009; 10: 410-5.
22. Cheah BC, Lin CS, Park SB, Vucic S, Krishnan AV, Kiernan MC. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012; 123: 2460-7.
23. Kuwabara S, Misawa S, Tamura N, Kanai K, Hiraga A, Ogawara K, et al. The effects of mexiletine on excitability properties of human median motor axons. Clin Neurophysiol. 2005; 116: 284-9.
24. Dong H, Xu L, Wu L, Wang X, Duan W, Li H, et al. Curcumin abolishes mutant TDP-43 induced excitability in a motor neuron-like cellular model of ALS. Neuroscience. 2014; 272: 141-53.
25. Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motor neuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014; 8: 24.
26. Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009; 66: 227-34.
27. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003; 61: 456-64.
28. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010; 17: 1199-942.
29. Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15: 610-7.
30. Manolis AS, Deering TF, Cameron J, Estes NA 3rd. Mexiletine: pharmacology and therapeutic use. Clin Cardiol. 1990; 13: 349-59.